Certified by Founder
Lodge
RheumaGen
start up
United States
- Denver, Colorado
- 10/01/2025
- Series A
- $15,000,000
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.
- Industry Biotechnology Research
- Website https://www.rheumagen.com/
- LinkedIn https://www.linkedin.com/company/rheumagen/
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)
Jupid | $840,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
Creati AI | $20,000,000 | (May 1, 2026)
Manifest OS | $60,000,000 | (May 1, 2026)
Iterative Health | $77,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Illuminant Surgical | $8,400,000 | (May 1, 2026)
BioOrbit | $13,334,811 | (May 1, 2026)
Parallel Web Systems | $100,000,000 | (Apr 30, 2026)
Fence | $20,000,000 | (Apr 30, 2026)
Certifyde | $2,000,000 | (Apr 30, 2026)